Cargando…

Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients

The survival time of patients with early clear cell renal cell carcinoma (ccRCC) is fairly long, but 20% to 30% of patients with localized tumors experience relapse, and the effect of IFN-α on survival has not been well studied in patients with early ccRCC. In this study, 208 patients with early ccR...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Hang, Liao, Cheng-Gong, Huang, Jian-Guo, Wang, Yong-Qiang, Li, Zheng, Fan, Lu-Lu, Qian, Men-Long, Wan, Nao, Lu, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762582/
https://www.ncbi.nlm.nih.gov/pubmed/29348897
http://dx.doi.org/10.18632/oncotarget.18567
_version_ 1783291715507978240
author Yin, Hang
Liao, Cheng-Gong
Huang, Jian-Guo
Wang, Yong-Qiang
Li, Zheng
Fan, Lu-Lu
Qian, Men-Long
Wan, Nao
Lu, Ning
author_facet Yin, Hang
Liao, Cheng-Gong
Huang, Jian-Guo
Wang, Yong-Qiang
Li, Zheng
Fan, Lu-Lu
Qian, Men-Long
Wan, Nao
Lu, Ning
author_sort Yin, Hang
collection PubMed
description The survival time of patients with early clear cell renal cell carcinoma (ccRCC) is fairly long, but 20% to 30% of patients with localized tumors experience relapse, and the effect of IFN-α on survival has not been well studied in patients with early ccRCC. In this study, 208 patients with early ccRCC were treated with surgery, and 54 of the patients received IFN-α as adjuvant therapy. The remaining 115 patients were treated with surgery but not with IFN-α therapy. The primary endpoint was the recurrence rate, 20.37% (11/54) and 33.04% (38/115) in the IFN-α and surgery-only group, respectively. The secondary endpoint was progression-free survival (PFS), which was 123.70 (95% CI: 107.18–140.22) months for the IFN-α group, and 95.80 (95% CI: 82.18–109.42) months for the non-IFN-α group; this difference was significant (P < 0.05). The main side effects were pyrexia (61.11%), muscle pain (24.07%), malaise (9.26%), anorexia (5.56%), hepatic dysfunction (3.70%) and renal dysfunction (1.85%). Moreover, a multivariate regression identified older age, higher BMI index and smoking as significant and independent predictors of decreased PFS (P < 0.05). Overall, IFN-α therapy significantly improved PFS in Chinese patients with early ccRCC and was an independent prognostic factor (P < 0.05). In conclusion, our study showed that adjuvant IFN-α therapy decreased the recurrence rate and prolonged PFS in patients with ccRCC. Thus, this treatment may help clinicians to select a better treatment modality and better predict survival in these patients.
format Online
Article
Text
id pubmed-5762582
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57625822018-01-18 Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients Yin, Hang Liao, Cheng-Gong Huang, Jian-Guo Wang, Yong-Qiang Li, Zheng Fan, Lu-Lu Qian, Men-Long Wan, Nao Lu, Ning Oncotarget Clinical Research Paper The survival time of patients with early clear cell renal cell carcinoma (ccRCC) is fairly long, but 20% to 30% of patients with localized tumors experience relapse, and the effect of IFN-α on survival has not been well studied in patients with early ccRCC. In this study, 208 patients with early ccRCC were treated with surgery, and 54 of the patients received IFN-α as adjuvant therapy. The remaining 115 patients were treated with surgery but not with IFN-α therapy. The primary endpoint was the recurrence rate, 20.37% (11/54) and 33.04% (38/115) in the IFN-α and surgery-only group, respectively. The secondary endpoint was progression-free survival (PFS), which was 123.70 (95% CI: 107.18–140.22) months for the IFN-α group, and 95.80 (95% CI: 82.18–109.42) months for the non-IFN-α group; this difference was significant (P < 0.05). The main side effects were pyrexia (61.11%), muscle pain (24.07%), malaise (9.26%), anorexia (5.56%), hepatic dysfunction (3.70%) and renal dysfunction (1.85%). Moreover, a multivariate regression identified older age, higher BMI index and smoking as significant and independent predictors of decreased PFS (P < 0.05). Overall, IFN-α therapy significantly improved PFS in Chinese patients with early ccRCC and was an independent prognostic factor (P < 0.05). In conclusion, our study showed that adjuvant IFN-α therapy decreased the recurrence rate and prolonged PFS in patients with ccRCC. Thus, this treatment may help clinicians to select a better treatment modality and better predict survival in these patients. Impact Journals LLC 2017-06-19 /pmc/articles/PMC5762582/ /pubmed/29348897 http://dx.doi.org/10.18632/oncotarget.18567 Text en Copyright: © 2017 Yin et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Clinical Research Paper
Yin, Hang
Liao, Cheng-Gong
Huang, Jian-Guo
Wang, Yong-Qiang
Li, Zheng
Fan, Lu-Lu
Qian, Men-Long
Wan, Nao
Lu, Ning
Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients
title Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients
title_full Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients
title_fullStr Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients
title_full_unstemmed Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients
title_short Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients
title_sort interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of chinese patients
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762582/
https://www.ncbi.nlm.nih.gov/pubmed/29348897
http://dx.doi.org/10.18632/oncotarget.18567
work_keys_str_mv AT yinhang interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients
AT liaochenggong interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients
AT huangjianguo interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients
AT wangyongqiang interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients
AT lizheng interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients
AT fanlulu interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients
AT qianmenlong interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients
AT wannao interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients
AT luning interferonaadjuvanttherapydecreasestherecurrenceofearlyclearcellrenalcellcarcinomaandimprovestheprognosisofchinesepatients